Results 101 to 110 of about 11,153 (206)

Bromocriptine: old drug, new formulation and new indication

, 2010
Bromocriptine is an ergot alkaloid dopamine D2 receptor agonist that has been used extensively in the past to treat hyperprolactinaemia, galactorrhoea and Parkinsonism.
Bailey, CJ, Holt, R. I. G., Barnett, A. H., Barnett, Anthony, A. H. Barnett, R. I. G. Holt, Holt, RIG, Bailey, C. J., C. J. Bailey   +8 more
core   +1 more source

Novel antiviral activity and mechanism of bromocriptine as a Zika virus NS2B-NS3 protease inhibitor

, 2017
Zika virus (ZIKV) infection is associated with congenital malformations in infected fetuses and severe neurological and other systemic complications in adults.
Cyril Chik-Yan Yip, Tee, KM, Chris Chung-Sing Chan, Vincent Kwok-Man Poon, Kenn Ka-Heng Chik, Chik, KKH, Poon, VKM, Kah-Meng Tee, Zhang, AJ, Yip, CCY, Jessica Oi-Ling Tsang, Zheng Zhu, Kin-Kui Lai, Zhu, Z, Chan, KH, Chan, CCS, Shuofeng Yuan, Kwok-Hung Chan, Chan, JFW, Richard Yi-Tsun Kao, Gang Lu, Yuan, S, Tsang, JOL, Lu, G, Anna Jinxia Zhang, Kwok-Yung Yuen, Lai, KK, Kao, RYT, Yuen, KY, Jasper Fuk-Woo Chan   +29 more
core   +1 more source

Haemodynamic effects of bromocriptine in the conscious spontaneously hypertensive rat

, 1984
The systemic haemodynamic effects of 0·3 mg kg−1 bromocriptine s.c. in conscious, chronically instrumented spontaneously hypertensive rats (SHR) has been investigated.
H A J Struyker-Boudier, H van Essen, J F M Smits   +2 more
core   +1 more source

Surgical Management of Gestational Gigantomastia: A Case Report Highlighting Therapeutic Intervention

Plastic and Reconstructive Surgery, Global Open
Summary:. Gigantomastia is an exceedingly rare condition characterized by extraordinary growth of breasts during pregnancy, and its underlying etiology remains elusive.
Misha A. Lemma, MD, Yisihak S. Debodina, MD, Martha F. Gebremedhin, MD, Meki K. Aman, MD, Don Eliseo III Lucero-Prisno, MD, MSc, PhD   +4 more
doaj   +1 more source

The effects of vaginal bromocriptine and dienogest on women with adenomyosis: a clinical study

Middle East Fertility Society Journal
Objective Adenomyosis occurs when endometrial glands and stroma develop in the myometrium, leading to symptoms such as pelvic pain and heavy menstrual bleeding. Method This randomized, double-blinded, controlled trial study was conducted on patients with
Parvane Bahoorzahi, Soheila Aminimoghaddam, Roya Derakhshan, Neda Hashemi, Samaneh Rokhgireh   +4 more
doaj   +1 more source

Supplemental Figure 3- Bromocriptine improves HOMA-ir in MC4R KO mice

, 2019
Bromocriptine treatment (filled bars) led to an improved HOMA index for MC4R KO mice as compared to vehicle treated (open bars) MC4R KO mice. * p < 0.05, 1-way ANOVA with Sidak’s multiple comparison test. 2-way ANOVA with Tukey’s multiple comparison test.
Sarah Framnes-DeBoer (7206893)
core   +1 more source

Co-Administration of Curcumin and Bromocriptine Nano-liposomes for Induction of Apoptosis in Lung Cancer Cells

Iranian Biomedical Journal, 2020
Background: In recent years, nanotechnology with modern advances in the macromolecular design of nano-carriers has proved to be helpful in the development of drugs delivery systems.
Mojgan Sheikhpour, Majid Sadeghizadeh, Fatemeh Yazdian, Ali Mansoori, Hassan Asadi, Abolfazl Movafagh, Seyed Sadegh Shahraeini   +6 more
doaj  

Bromocriptine is ineffective in the treatment of chronic nonfluent aphasia

, 1995
The effect of bromocriptine on chronic nonfluent aphasia was investigated in 4 patients suffering from a stroke 24 to 35 months before the onset of this study (average 29 months).
Ozeren A., Sarica Y., Mavi H., Demirkiran M.   +3 more
core  

Nasal spray bromocriptine: Effects on serum prolactin in puerperal women

, 1996
BACKGROUND: The objective of this study was to investigate the effectiveness of a single nasal spray administration of 0.8 mg bromocriptine in reducing PRL serum levels.
PETRUZZI D., SCHONAUER L. M., RAGNO G., RUCCIA C., MATTEO, MARIA, CICINELLI E.   +5 more
core  

Severe leukopenia and mild thrombocytopenia after chronic bromocriptine (CB-154) administration

, 1981
A 23-year-old woman was receiving bromocriptine (CB-154, 7.5-10 mg/day, for a hyperprolactinemic galactorrhea-amenorrhea syndrome. She also had insulin-dependent diabetes.
FERDEGHINI, Marco, O. Giampietro, M. Petrini   +2 more
core